Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity
Shots:
- The company plan to initiate a pivotal P-IIIa program to assess the efficacy and safety of oral semaglutide (50mg) vs PBO in ~1000 people with obesity or overweight with comorbidities for 68wks.
- The initiation follows the completion of the STEP P-IIIa clinical program with semaglutide (2.4mg- qw- SC). The study is expected to initiate the study in H2’21
- Oral semaglutide is a convenient and effective treatment option for people with obesity and HCPs enabling broader use of anti-obesity medication
Ref: Globe Newswire | Image: Mehr News Agency
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com